Skip to content

Renal Sympathetic Denervation in Mild Refractory Hypertension

Renal Sympathetic Denervation in Patients With Mild Refractory Hypertension

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01656096
Enrollment
71
Registered
2012-08-02
Start date
2012-07-31
Completion date
2014-07-31
Last updated
2016-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory Hypertension

Brief summary

The purpose of this study is to examine the benefit of renal sympathetic denervation in patients with mild refractory hypertension

Interventions

DEVICERenal sympathetic denervation (Symplicity ablation catheter, Medtronic Inc. Minneapolis, Minnesota, USA)
OTHERSham procedure

Sponsors

University of Leipzig
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Refractory hypertension: 3 or more antihypertensive agents of different classes (including a diuretic) at optimal dosage without change in the 4 weeks preceding randomization * Systolic blood pressure of 135-149 and/or diastolic blood pressure of 90-94 mmHg (ABPM mean daytime values) * No change in blood pressure medication within 6 months after randomization * Age 18 to 75 years * Informed consent

Exclusion criteria

* Blood pressure outside range mentioned above * Renal, aortic or pelvic anatomy unsuited for renal sympathetic denervation * Estimated glomerular filtration rate \<45 mL/min/1.73 m² (modification of diet in renal disease formula) * Unstable angina pectoris * Myocardial infarction within 6 months prior to randomization * Planned surgery or cardiovascular intervention within 6 months after randomization * Severe heart valve disease * Severe comorbidities with limited life expectancy * Pregnancy * Participation in another trial

Design outcomes

Primary

MeasureTime frame
Change in systolic blood pressure (ABPM mean value)6 months

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026